Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America最新文献

筛选
英文 中文
Genetic Epidemiology reveals three chronic reservoir areas with recurrent population mobility challenging poliovirus eradication in Pakistan. 遗传流行病学揭示了巴基斯坦三个具有复发性人口流动的慢性储藏区,对根除脊髓灰质炎病毒构成挑战。
Ribqa Akhtar, Nayab Mahmood, M. Alam, M. Naeem, S. Zaidi, Salman Sharif, Zainab Khattak, Y. Arshad, A. Khurshid, G. Mujtaba, L. Rehman, M. Angez, S. Shaukat, N. Mushtaq, M. Umair, A. Ikram, M. Salman
{"title":"Genetic Epidemiology reveals three chronic reservoir areas with recurrent population mobility challenging poliovirus eradication in Pakistan.","authors":"Ribqa Akhtar, Nayab Mahmood, M. Alam, M. Naeem, S. Zaidi, Salman Sharif, Zainab Khattak, Y. Arshad, A. Khurshid, G. Mujtaba, L. Rehman, M. Angez, S. Shaukat, N. Mushtaq, M. Umair, A. Ikram, M. Salman","doi":"10.1093/cid/ciz1037","DOIUrl":"https://doi.org/10.1093/cid/ciz1037","url":null,"abstract":"BACKGROUND\u0000Pakistan is among three countries endemic for wild poliovirus (WPV1) circulation, still struggling for eradication of poliomyelitis. Active clinical and environmental surveillance systems with meticulous laboratory investigations provide insights into poliovirus transmission patterns and genomic diversity to inform decisions for strategic operations required to achieve eradication.\u0000\u0000\u0000METHODS\u0000We analyzed epidemiological and virological data at molecular level to comprehend the current epidemiological status of WPV1 in Pakistan during 2015-2017. Stool specimens of AFP patients and sewage samples collected from 60 active environmental sites. Viral culturing, intratypic differentiation by real time-PCR and nucleic acid sequencing of VP1 region of poliovirus genome to determine the genetic relatedness among WPV1 strains were applied. The phylogenetic analysis were done using BEAST v2.3.0 [1] .\u0000\u0000\u0000RESULTS\u0000Poliovirus isolates were grouped into eleven distinct clusters which had ≥95% nucleotide homology in VP1 coding region. Most burden of poliovirus was shared by three major reservoirs i.e. Karachi, Peshawar and Quetta block (64.2% in 2015; 75.4% in 2016 and 76.7% in 2017).\u0000\u0000\u0000CONCLUSIONS\u0000Environmental surveillance reveals importations and pockets of unimmunized children which dictate intensive target mop-up campaigns in such areas to contain poliovirus transmission. Decrease in number of orphan isolates reflects effective combination of AFP and ES surveillance working in Pakistan. The genetic data reflects sustained transmission within reservoir areas, further expanded by periodic importations to areas of high immunity reflected by immediate termination of imported viruses. However, it is suggestive that Pakistan is at-risk unless the entire country including Afghanistan attain a polio-free status. Improved immunization coverage with high quality surveillance is vital for global certification.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83327060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Antibiotic prescribing before and after the diagnosis of comorbidity: a cohort study using primary care electronic health records. 合并症诊断前后的抗生素处方:使用初级保健电子健康记录的队列研究
P. Rockenschaub, A. Hayward, L. Shallcross
{"title":"Antibiotic prescribing before and after the diagnosis of comorbidity: a cohort study using primary care electronic health records.","authors":"P. Rockenschaub, A. Hayward, L. Shallcross","doi":"10.1093/cid/ciz1016","DOIUrl":"https://doi.org/10.1093/cid/ciz1016","url":null,"abstract":"BACKGROUND\u0000Comorbidities like diabetes or COPD increase patients' susceptibility to infections, but it is unclear how the onset of comorbidity impacts antibiotic use. We aimed to estimate rates of antibiotic use before and after diagnosis of comorbidity in primary care to identify opportunities for antibiotic stewardship.\u0000\u0000\u0000METHODS\u0000We analysed UK primary care records from the Clinical Practice Research Datalink (CPRD) database. Adults registered between 2008-2015 without prior comorbidity diagnoses were eligible for inclusion. Monthly adjusted rates of antibiotic prescribing were estimated for patients with new-onset stroke, coronary heart disease, heart failure, peripheral arterial disease, asthma, chronic kidney disease, diabetes or COPD in the 12 months before and after diagnosis, and for controls without comorbidity.\u0000\u0000\u0000RESULTS\u0000106,540 / 1,071,94 (9.9%) eligible patients were diagnosed with comorbidity. Antibiotic prescribing rates increased 1.9-2.3 fold in the 4-9 months preceding diagnosis of asthma, heart failure and COPD, before declining to stable levels within 2 months after diagnosis. A less marked trend was seen for diabetes (Rate ratio 1.55, 95%-CI: 1.48-1.61). Prescribing rates for patients with vascular conditions increased immediately before diagnosis and remained 30-39% higher than baseline afterwards. Rates of prescribing to controls increased by 17-28% in the months just before and after consultation.\u0000\u0000\u0000CONCLUSIONS\u0000Antibiotic prescribing increased rapidly before diagnosis of conditions presenting with respiratory symptoms (COPD, heart failure, asthma), and declined afterwards. This suggests onset of respiratory symptoms may be misdiagnosed as infection. Earlier diagnosis of these comorbidities could reduce avoidable antibiotic prescribing.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"53 4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79867861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings. 筛选ACTG A5288的不同HIV-1耐药谱:在资源有限的情况下,二线抗逆转录病毒治疗出现病毒学失败的人的研究
Carole L Wallis, Michael D Hughes, Justin Ritz, Raquel Viana, Carlos Silva de Jesus, Shanmugam Saravanan, Marije van Schalkwyk, Rosie Mngqibisa, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Laura Hovind, Linda Wieclaw, Robert Gross, Catherine Godfrey, Ann C Collier, Beatriz Grinsztejn, John W Mellors
{"title":"Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.","authors":"Carole L Wallis, Michael D Hughes, Justin Ritz, Raquel Viana, Carlos Silva de Jesus, Shanmugam Saravanan, Marije van Schalkwyk, Rosie Mngqibisa, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Laura Hovind, Linda Wieclaw, Robert Gross, Catherine Godfrey, Ann C Collier, Beatriz Grinsztejn, John W Mellors","doi":"10.1093/cid/ciz1116","DOIUrl":"10.1093/cid/ciz1116","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) drug resistance profiles are needed to optimize individual patient management and to develop treatment guidelines. Resistance profiles are not well defined among individuals on failing second-line antiretroviral therapy (ART) in low- and middle-income countries (LMIC).</p><p><strong>Methods: </strong>Resistance genotypes were performed during screening for enrollment into a trial of third-line ART (AIDS Clinical Trials Group protocol 5288). Prior exposure to both nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs and confirmed virologic failure on a protease inhibitor-containing regimen were required. Associations of drug resistance with sex, age, treatment history, plasma HIV RNA, nadir CD4+T-cell count, HIV subtype, and country were investigated.</p><p><strong>Results: </strong>Plasma HIV genotypes were analyzed for 653 screened candidates; most had resistance (508 of 653; 78%) to 1 or more drugs. Genotypes from 133 (20%) showed resistance to at least 1 drug in a drug class, from 206 (32%) showed resistance to at least 1 drug in 2 drug classes, and from 169 (26%) showed resistance to at least 1 drug in all 3 commonly available drug classes. Susceptibility to at least 1 second-line regimen was preserved in 59%, as were susceptibility to etravirine (78%) and darunavir/ritonavir (97%). Susceptibility to a second-line regimen was significantly higher among women, younger individuals, those with higher nadir CD4+ T-cell counts, and those who had received lopinavir/ritonavir, but was lower among prior nevirapine recipients.</p><p><strong>Conclusions: </strong>Highly divergent HIV drug resistance profiles were observed among candidates screened for third-line ART in LMIC, ranging from no resistance to resistance to 3 drug classes. These findings underscore the need for access to resistance testing and newer antiretrovirals for the optimal management of third-line ART in LMIC.</p>","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"14 1","pages":"e170-e177"},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73677142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pneumonia and Electronic Health Records-a window into disease, a mirror of our behavior, or just another streetlight? 肺炎和电子健康记录——一扇了解疾病的窗口,一面反映我们行为的镜子,还是另一盏路灯?
B. Jones, Makoto M. Jones
{"title":"Pneumonia and Electronic Health Records-a window into disease, a mirror of our behavior, or just another streetlight?","authors":"B. Jones, Makoto M. Jones","doi":"10.1093/cid/ciz1053","DOIUrl":"https://doi.org/10.1093/cid/ciz1053","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89214393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Tackling Infectious Diarrhea in Hematopoietic Cell Transplantation. 造血细胞移植治疗感染性腹泻。
Jennifer L. Saullo, C. Polage
{"title":"Tackling Infectious Diarrhea in Hematopoietic Cell Transplantation.","authors":"Jennifer L. Saullo, C. Polage","doi":"10.1093/cid/ciz1072","DOIUrl":"https://doi.org/10.1093/cid/ciz1072","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"243 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75993890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Maternal antibodies against influenza in cord blood and protection against laboratory-confirmed influenza in infants. 脐带血中抗流感的母体抗体和对实验室确认的婴儿流感的保护。
B. Cowling, Ranawaka A.P.M Perera, V. Fang, D. Chu, A. P. Hui, Anita P C Yeung, J. Peiris, W. Wong, E. L. Chan, S. Chiu
{"title":"Maternal antibodies against influenza in cord blood and protection against laboratory-confirmed influenza in infants.","authors":"B. Cowling, Ranawaka A.P.M Perera, V. Fang, D. Chu, A. P. Hui, Anita P C Yeung, J. Peiris, W. Wong, E. L. Chan, S. Chiu","doi":"10.1093/cid/ciz1058","DOIUrl":"https://doi.org/10.1093/cid/ciz1058","url":null,"abstract":"BACKGROUND\u0000Studies that correlate maternal antibodies with protection from influenza A or B virus infection in young infants in areas with prolonged influenza circulation are lacking.\u0000\u0000\u0000METHODS\u0000We conducted a prospective, observational study to evaluate the effects of maternal-transferred antibodies against influenza A and B viruses against laboratory-confirmed influenza in a cohort born over 24 months. Cord blood samples were retrieved at birth and infants were actively followed for the first 6 months of life. Nasal swabs were collected and tested for influenza A and B by RT-PCR whenever an illness episode was identified. Cord blood samples were tested by the hemagglutination inhibition (HAI) assay to viruses that circulated during the follow-up period.\u0000\u0000\u0000RESULTS\u00001162 infants were born to 1140 recruited women: 1092 (94%) infants completed 6 months of follow-up. Proportions of cord blood with HAI antibodies titers ≥40 against A(H1N1), A(H3N2), B/Victoria and B/Yamagata were 31%, 24%, 31% and 54%, respectively. Only 4% of women had maternal influenza vaccination. Cord blood antigen-specific HAI titers ≥40 were found to correlate with protection from infection only for influenza B/Yamagata. No influenza B virus infection occurred in infants ≤60 days of life. Proportional hazards analysis showed that a cord blood HAI titer of 40 was associated with 83% (95% confidence interval: 44%, 95%) reduction in the risk of influenza B/Yamagata infections compared to a cord blood titer <10.\u0000\u0000\u0000CONCLUSIONS\u0000We documented that maternal immunity against influenza B/Yamagata was conferred to infants within the first 6 months of life.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82599053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Quantifying the burden of congenital CMV infection (cCMV) with long-term sequelae in subsequent pregnancies of women seronegative at their first pregnancy. 首次妊娠时血清阴性的妇女在随后妊娠中先天性巨细胞病毒感染(cCMV)的长期后遗症的量化负担
M. Leruez-Ville, T. Guilleminot, J. Stirnemann, L. Salomon, E. Spaggiari, V. Faure-Bardon, J. Magny, Y. Ville
{"title":"Quantifying the burden of congenital CMV infection (cCMV) with long-term sequelae in subsequent pregnancies of women seronegative at their first pregnancy.","authors":"M. Leruez-Ville, T. Guilleminot, J. Stirnemann, L. Salomon, E. Spaggiari, V. Faure-Bardon, J. Magny, Y. Ville","doi":"10.1093/cid/ciz1067","DOIUrl":"https://doi.org/10.1093/cid/ciz1067","url":null,"abstract":"BACKGROUND\u0000In women seronegative before pregnancy, cCMV related sequelae are exclusively seen in those infected in the first trimester of pregnancy. Up to 30% of infected neonates following maternal primary infection in the first trimester suffer long-term sequelae. Maternal parity is an established risk factor of cCMV in previously seronegative women.\u0000\u0000\u0000OBJECTIVE\u0000to quantify the risk of cCMV and related sequelae following primary infection in the first trimester in subsequent pregnancies in a population of women seronegative at their first pregnancy.\u0000\u0000\u0000METHODS\u0000739 women seronegative at their first pregnancy had at least one of 971 subsequent pregnancies and deliveries managed at our institution. All women had CMV IgG and IgM testing at 11-14 weeks' of each pregnancy.\u0000\u0000\u0000RESULTS\u000015.6% (115/739) of women seroconverted between 2 consecutive pregnancies. 29% (33/115) of seroconversions occurred in the periconceptional period or in the first trimester. The risks for cCMV and related sequelae (neurologic and/or hearing loss) following maternal infection in the first trimester were respectively 24 and 6-fold higher (RR [95%CI] =24 [10.8-62.3] and 6 [1.5-24]) than the general pregnant population. 88% (29/33) and 92% (11/12) of, respectively, all primary maternal infections and fetal infections in the 1st trimester occurred when the inter-pregnancy interval was ≤2 years.\u0000\u0000\u0000CONCLUSION\u0000Women seronegative at their first pregnancy with a subsequent pregnancy within 2 years have the highest risk of delivering a child with cCMV-related sequelae. These women should be made aware of the risk and given the opportunity of serology screening in the first trimester.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77152128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults 流感疫苗预防免疫功能低下成人经实验室证实的流感住院的有效性
K. Hughes, D. Middleton, M. Nowalk, G. Balasubramani, E. Martin, M. Gaglani, H. Talbot, M. Patel, J. Ferdinands, R. Zimmerman, F. Silveira, R. Zimmerman, D. Middleton, F. Silveira, K. Hughes, H. Eng, Theresa M. Sax, Sean G. Saul, Charles Rinaldo, Balasubramani Goundappa, M. Nowalk, Lori Steiffel, J. Williams, Monika Johnson, M. Gaglani, Kempapura Murthy, T. McNeal, Shekar Ghamande, V. Escobedo, Anne Robertson, Lydia Clipper, A. Rao, K-H Chang, Marcus Volz, K. Walker, A. Arroliga, A. Monto, Emily K. Martin, R. Malosh, J. Petrie, A. Lauring, Caroline K. Cheng, H. Segaloff, E. McSpadden, Emileigh Johnson, Rachel K Truscon, L. Lamerato, S. Davis, M. Zervos, H. Talbot, Dayna Wyatt, Yuwei Zhu, Zhouwen Liu, Rendie Mchenry, N. Halasa, Sandra Alvarez Calvillo, Stephanie Longmire, Laura S. Stewart, J. Ferdinands, A. Fry, E. Alyanak, Emily R Smith, Courtney Strickland, Sarah M. Spencer, B. Flannery, J. Chung, Xiyan Xu, Stephen L. Lindstrom, L. Berman, W. Sessions, Rebecca J. Kondor, M. Patel
{"title":"Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults","authors":"K. Hughes, D. Middleton, M. Nowalk, G. Balasubramani, E. Martin, M. Gaglani, H. Talbot, M. Patel, J. Ferdinands, R. Zimmerman, F. Silveira, R. Zimmerman, D. Middleton, F. Silveira, K. Hughes, H. Eng, Theresa M. Sax, Sean G. Saul, Charles Rinaldo, Balasubramani Goundappa, M. Nowalk, Lori Steiffel, J. Williams, Monika Johnson, M. Gaglani, Kempapura Murthy, T. McNeal, Shekar Ghamande, V. Escobedo, Anne Robertson, Lydia Clipper, A. Rao, K-H Chang, Marcus Volz, K. Walker, A. Arroliga, A. Monto, Emily K. Martin, R. Malosh, J. Petrie, A. Lauring, Caroline K. Cheng, H. Segaloff, E. McSpadden, Emileigh Johnson, Rachel K Truscon, L. Lamerato, S. Davis, M. Zervos, H. Talbot, Dayna Wyatt, Yuwei Zhu, Zhouwen Liu, Rendie Mchenry, N. Halasa, Sandra Alvarez Calvillo, Stephanie Longmire, Laura S. Stewart, J. Ferdinands, A. Fry, E. Alyanak, Emily R Smith, Courtney Strickland, Sarah M. Spencer, B. Flannery, J. Chung, Xiyan Xu, Stephen L. Lindstrom, L. Berman, W. Sessions, Rebecca J. Kondor, M. Patel","doi":"10.1101/2020.10.08.20208579","DOIUrl":"https://doi.org/10.1101/2020.10.08.20208579","url":null,"abstract":"Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults. Methods: We analyzed data from adults [≥] 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariate logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations. Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (-29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term). Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78109959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Risk of neurological disorders in patients with European Lyme neuroborreliosis. A nationwide population-based cohort study. 欧洲莱姆病患者神经系统疾病的风险。一项基于全国人群的队列研究。
R. Haahr, M. M. Tetens, R. Dessau, K. Krogfelt, J. Bodilsen, N. S. Andersen, J. Møller, Casper Roed, C. Christiansen, S. Ellermann-Eriksen, J. Bangsborg, K. Hansen, T. Benfield, C. Ø. Andersen, N. Obel, A. Lebech, L. Omland
{"title":"Risk of neurological disorders in patients with European Lyme neuroborreliosis. A nationwide population-based cohort study.","authors":"R. Haahr, M. M. Tetens, R. Dessau, K. Krogfelt, J. Bodilsen, N. S. Andersen, J. Møller, Casper Roed, C. Christiansen, S. Ellermann-Eriksen, J. Bangsborg, K. Hansen, T. Benfield, C. Ø. Andersen, N. Obel, A. Lebech, L. Omland","doi":"10.1093/cid/ciz997","DOIUrl":"https://doi.org/10.1093/cid/ciz997","url":null,"abstract":"BACKGROUND\u0000Lyme neuroborreliosis (LNB) caused by the tick-borne spirochetes of the Borrelia burgdorferi sensu lato species complex has been suggested to be associated with a range of neurological disorders. In a nationwide population-based cohort-study we examined the association between LNB and dementia, Alzheimer's disease, Parkinson's disease, motor neuron disease, epilepsy and Guillain-Barré syndrome.\u0000\u0000\u0000METHODS\u0000We used national registers to identify all Danish residents diagnosed during 1986-2016 with LNB (n=2,067) and a gender and age matched comparison cohort from the general population (n=20,670), and calculated risk estimates and hazard ratios (HR).\u0000\u0000\u0000RESULTS\u0000We observed no long-term increased risk of dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases or epilepsy. However, within the first year eight (0.4%) of the LNB patients developed epilepsy compared with 20 (0.1%) of the comparison cohort (difference 0.3%, 95% CI: 0.02% to 0.6%). In the LNB group 11 (0.5%) patients were diagnosed with Guillain-Barré syndrome within the first year after LNB diagnosis compared with 0 (0.0%) in the comparison cohort. After the first year, the risk of Guillain-Barré was not increased.\u0000\u0000\u0000CONCLUSION\u0000LNB patients did not have increased long-term risk of dementia, Alzheimer's disease, Parkinson's disease, motor neuron diseases, epilepsy or Guillain-Barré. Although absolute risk is low, LNB patients might have an increased short-term risk of epilepsy and Guillain-Barré syndrome.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89359475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 17
Diagnostic Stewardship for Clostridiodes difficile testing: From Laxatives to Diarrhea and Beyond. 艰难梭菌检测的诊断管理:从泻药到腹泻及其他。
C. Rock, L. Maragakis
{"title":"Diagnostic Stewardship for Clostridiodes difficile testing: From Laxatives to Diarrhea and Beyond.","authors":"C. Rock, L. Maragakis","doi":"10.1093/cid/ciz982","DOIUrl":"https://doi.org/10.1093/cid/ciz982","url":null,"abstract":"","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78607240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信